Scopus BioPharma Inc. (NASDAQ:SCPS) Short Interest Update

Scopus BioPharma Inc. (NASDAQ:SCPS – Get Rating) was the recipient of a large decline in short interest during the month of March. As of March 31st, there was short interest totalling 75,200 shares, a decline of 23.7% from the March 15th total of 98,600 shares. Currently, 1.1% of the company’s stock are sold short. Based on an average trading volume of 322,300 shares, the days-to-cover ratio is presently 0.2 days.

A number of institutional investors and hedge funds have recently bought and sold shares of the business. M&R Capital Management Inc. purchased a new position in Scopus BioPharma during the 1st quarter worth $53,000. Virtu Financial LLC purchased a new position in Scopus BioPharma during the 4th quarter worth $25,000. Citadel Advisors LLC bought a new stake in shares of Scopus BioPharma during the 4th quarter worth $34,000. Geode Capital Management LLC bought a new stake in shares of Scopus BioPharma during the 4th quarter worth $108,000. Finally, Renaissance Technologies LLC bought a new stake in shares of Scopus BioPharma during the 4th quarter worth $34,000. 18.89% of the stock is currently owned by hedge funds and other institutional investors.

SCPS traded down $0.01 during mid-day trading on Monday, reaching $0.64. 1 shares of the stock were exchanged, compared to its average volume of 296,351. The company has a 50 day moving average price of $0.74 and a two-hundred day moving average price of $1.89. Scopus BioPharma has a 1 year low of $0.57 and a 1 year high of $19.95.

About Scopus BioPharma (Get Rating)

Scopus BioPharma Inc, a biopharmaceutical company, focuses on developing transformational therapeutics targeting serious diseases. Its lead development programs are immuno-oncology gene therapy for the treatment of various cancers, which include CO-sTiRNA, a STAT3 inhibitor gene therapy that drives tumor cell growth and anti-tumor immune suppression; and MRI-1867, a cannabinoid-1 receptor inverse agonist and inhibitor of inducible nitric oxide synthase for the treatment of systemic sclerosis.

Featured Stories